Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 52

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Spinal muscular atrophy

Not yet recruiting

Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Subarachnoid haemorrhage+4

Not yet recruiting

Prehospital Sedation with Esketamine versus Propofol in Patients with Severe Acute Brain Injury

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Rigshospitalet

Fabry's disease

Not yet recruiting

Efficacy and Safety of Lucerastat in Treatment‑Naïve Adult Male Patients with Fabry Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Fondation A De Rothschild

Partial seizures

Not yet recruiting

Safety and tolerability of OV329 as add‑on therapy in adults with drug‑resistant focal epilepsy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

Glioblastoma multiforme

Not yet recruiting

Study of autologous mature dendritic cell vaccine plus atezolizumab in patients with recurrent glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Central nervous system vasculitis

Not yet recruiting

Rituximab versus azathioprine for remission maintenance in patients with primary angiitis of the central nervous system – randomized controlled trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Cerebrovascular accident

Not yet recruiting

Rimonabant for Improving Walking Ability in Post‑Stroke Patients in the Chronic Phase

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Dementia Alzheimer's type

Not yet recruiting

A Phase 2 Study of TML-6 in Adults with Early Alzheimer’s Disease to Evaluate Safety, Tolerability, and Efficacy

Investigational
Countries:SwedenSweden
  • Participants:65+ years

Amyotrophic lateral sclerosis

Not yet recruiting

Randomized Placebo‑Controlled Trial of Colchicine to Slow Disease Progression in Adults with Amyotrophic Lateral Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Cerebrovascular accident

Not yet recruiting

Effect of Rimonabant on Functional Recovery in Subacute Stroke Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.